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Glioblastoma-targeted drug delivery systems facilitate efﬁcient delivery of chemotherapeutic agents to ma-
lignant gliomas,whileminimizing systemic toxicityand side effects. Taking advantage of theﬁbrin deposition
that is characteristic of tumors, we constructed spherical, Cy7-labeled, targeting micelles to glioblastoma
through theadditionof theﬁbrin-bindingpentapeptide, cysteineearginineeglutamicacidelysineealanine, or
CREKA. Conjugation of the CREKA peptide to Cy7-micelles increased the average particle size and zeta po-
tential. Upon intravenous administration to GL261 glioma bearing mice, Cy7-micelles passively accumulated
at the brain tumor site via the enhanced permeability and retention (EPR) effect, and Cy7-CREKA-micelles
displayed enhanced tumor homing via active targeting as early as 1 h after administration, as conﬁrmed via
in vivo and ex vivo imaging and immunohistochemistry. Biodistribution of micelles showed an accumulation
within the liver and kidneys, leading to micelle elimination via renal clearance and the reticuloendothelial
system (RES). Histological evaluation showed no signs of cytotoxicity or tissue damage, conﬁrming the safety
and utility of this nanoparticle system for delivery to glioblastoma. Our ﬁndings offer strong evidence for the
glioblastoma-targetingpotential ofCREKA-micelles andprovide the foundation forCREKA-mediated, targeted
therapy of glioma.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction critical regions for brain function, unavoidably resulting in tu-Gliomas are primary brain tumors that are derived from as-
trocytes, oligodendrocytes, or ependymal cells. Glioblastoma
multiforme (GBM), a grade IV astrocytoma, accounts for 70% of
all malignant gliomas and carries a 5-year survival rate of less
than 5% with a 14.6-month median survival time even with the
treatment of aggressive radiotherapy and concomitant or adju-
vant temozolomide [1,2]. Treatment of glioblastoma represents
one of the most formidable challenges in oncology due to the
inability to completely surgically resect the tumor owing to a
diffuse invasion of the surrounding normal brain tissue. The
amount of tumor removed is also limited by a proximity to: þ1 773 834 7756.
: þ1 773 834 2608.
edu (M.S. Lesniak), mtirrell@
r Ltd. Open access under CC BY-NC-NDmor recurrence [3]. Consequently, post-surgical chemotherapy
regimens are considered to be essential for the treatment of
gliomas, but therapeutic advancement for GBM has remained
disappointing due to poor penetration of chemotherapy agents
successfully crossing the bloodebrain-barrier (BBB) [4].
Although this interface acts to protect the brain from exposure to
harmful substances circulating in the bloodstream under normal
physiological conditions, the BBB simultaneously limits pene-
tration of drugs to cancerous tissue, even when partially
compromised [5,6].
Recent developments in nanoparticle technology have yielded
promising results in the delivery of therapeutic agents across the
BBB [7e9]. Micelles are of particular interest due to their small size,
biocompatibility, and hydrophobic core, which is especially ad-
vantageous for loading poorly soluble drugs [10]. When properly
designed, micelles can prolong drug bioavailability in circulation
and deliver drugs in the optimum dosage range, which results in
improved therapeutic efﬁcacy and reduced toxic side effects [11].
Importantly, micelles have been shown to chaperone chemo-
therapy agents across the BBB as active targeting drug delivery
systems in addition to passively targeting tumor tissue via the license.
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surface-modiﬁcations with ligands such as transferrin, epidermal
growth factor, folate, and a2-glycoprotein, micelles can bind to
receptors that are selectively expressed on cancer cells or the tumor
vasculature [10,13e15].
Previous reports demonstrate GBM is accompanied by leaky,
hemorrhagic vasculature, which contributes to thrombosis and
ﬁbrin deposition [16]. The presence of ﬁbrin and proteins that
become cross-linked to ﬁbrin in tumors, but not in normal tis-
sues, are thought to be a result of the leakiness of tumor vessels,
which allows plasma proteins to enter from the blood into tumor
tissue where ﬁbrinogen is converted to ﬁbrin via tissue pro-
coagulant factors [17]. Since ﬁbrin deposition within and
around the tumor area is characteristic to primary and metastatic
brain tumors, we examined the targeting capabilities of micelle
nanoparticles functionalized with the clot-binding peptide,
cysteineearginineeglutamic acidelysineealanine (CREKA) [18e
20]. In our earlier studies, ﬂuorescently-labeled micelles func-
tionalized with the CREKA pentapeptide were reported to home
to sites of ﬁbrin found on thrombotic, atherosclerotic plaques
[21]. Furthermore, CREKA has also been shown to target breast
and prostate cancer by binding to ﬁbrin and ﬁbrin-associated
clotted plasma proteins within the tumor vasculature [18,20].
For the ﬁrst time, the potential of CREKA-micelles as a targeting
nanoparticle system for gliomas via active binding to ﬁbrin
within the tumor blood vessels was investigated in this study. To
this end, peptide amphiphiles consisting of the CREKA peptide
were used to self-assemble targeting micelles. We intravenously
injected Cy7 labeled micelles with or without the CREKA peptide
to mice bearing intracranial glioma tumors and hypothesized
that the micelles would be capable of targeting brain tumor
tissue through the EPR effect and that the CREKA modiﬁcation
could further enhance tumor homing of the micelles by binding
to intravascular clots as well as interstitial areas of ﬁbrin depo-
sition (Fig. 1). In addition to targeting, the clearance properties of
these micelles were evaluated for up to 7 days.Fig. 1. Schematic of Cy7-micelle and Cy7-CREKA-micelle targe2. Materials and methods
2.1. CREKA micelle synthesis
The [CyseArgeGlueLyseAla] peptide was synthesized using standard Fmoc-
mediated solid phase peptide synthesis methods on rink Amide resin (Anaspec,
Fremont, CA, USA) using an automated PS3 Benchtop Peptide Synthesizer (Protein
Technologies, Tucson, AZ, USA). Peptides were cleaved and deprotected with
94:2.5:2.5:1 by volume triﬂuoroacetic acid:1,2-ethanedithiol:H2O:triisopropylsilane
andwere precipitated andwashed several times with cold diethyl ether, dissolved in
water, lyophilized, and stored as lyophilized powders at 20 C. Crude, peptide
mixtures were puriﬁed by reverse-phase HPLC (Prominence, Shimadzu, Columbia,
MD, USA) on a C8 column (Waters, Milford, MA) at 55 C using 0.1% triﬂuoroacetic
acid in acetonitrile/water mixtures and characterized by MALDI-TOF/TOF mass
spectral analysis (Biﬂex III, Bruker, Billerica, MA, USA). Cysteine-containing peptides
were conjugated via a thioether linkage to DSPE-PEG(2000)-maleimide (Avanti
Polar Lipids, Alabaster, AL, USA) by adding a 10% molar excess of the lipid to peptide
in water. After reaction at RT for 24 h, the resulting product was puriﬁed and
characterized as described above. Cy7 was conjugated via a peptide bond to DSPE-
PEG(2000)-amine (Avanti Polar Lipids, Alabaster, AL, USA) by adding an equal molar
equivalent of Cy7 mono-N-hydroxysuccinimide ester (GE Healthcare Life Sciences,
Pittsburgh, PA, USA) to the lipid dissolved in 10 mM aqueous sodium carbonate
buffer (pH 8.5). After reaction at RT for 24 h, the mixture was also puriﬁed on a C4
column and characterized as described above.
CREKA micelles were assembled by dissolving the Cy7 and peptide containing
DSPE-PEG(2000) amphiphiles in methanol (10:90 molar ratio), mixing the compo-
nents, and evaporating the mixed solution under nitrogen. The resulting ﬁlm was
dried under vacuum O/N, and then hydrated at 80 C for 30 min in water or PBS and
allowed to cool to RT. Non-targeting micelles were assembled by combing DSPE-
PEG(2000)-Cy7 and DSPE-PEG(2000)-maleimide.
2.2. Micelle characterization
2.2.1. Critical micelle concentration determination via 1,6-diphenyl-1,3,5-hexatriene
(DPH) ﬂuorescence
The critical micelle concentration (CMC) was determined using DPH ﬂuores-
cence [22]. This method relies on an increase in DPH ﬂuorescence as it partitions
from aqueous solution into the hydrophobic micelle core. Solutions of the CREKA
peptide amphiphile (PA) ranged in concentrations from 316 to 0.01 mM. DPH was
dissolved in tetrahydrofuran (THF) and a small amount of this solutionwas added to
each PA solution to achieve 1 mM DPH with a residual THF volume percentage of
approximately 0.1. Solutions containing PA and DPH were allowed to equilibrate for
1 h prior to measurement using a Tecan Inﬁnite 200 plate reader (Mannedorf,
Switzerland). DPH was excited at 350 nm and ﬂuorescence emission was measured
at 428 nm.ting glioma via the EPR effect and active binding to ﬁbrin.
Table 1
Size and zeta potential of micelles.
Cy7 Cy7-CREKA
Diameter (nm) 7.6  1.2 8.2  1.2
ZP (mV) 27.4  4.5 12.6  1.6
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Stock solutions of 100 mM DSPE-PEG(2000)-Cy7 and DSPE-PEG(2000)-CREKA in
PBS were used to conﬁrm the presence of small spheroidal micelles and DLS mea-
surements were determined at 90  and 637 nm using a Brookhaven Instruments
(Holtzville, NY, USA) system consisting of a BI-200SM goniometer and a BI-9000AT
autocorrelator.
2.2.3. Transmission electron microscopy (TEM)
Negative staining samples for TEM were prepared by placing the CREKA PA
solution on 400 mesh lacey carbon grids (Ted Pella, Redding, CA, USA) for 2 min.
Excess liquid waswicked away with ﬁlter paper and the grid waswashed withMilli-
Q water before placing 1 wt.% phosphotungstic acid solution for 2 min and washing
with Milli-Q water. Dried samples were imaged on a JEOL 1230 TEM, immediately
(JEOL, Ltd., Tokyo, Japan).
2.2.4. Zeta potential
Zetapotentialof100mMDSPE-PEG(2000)-Cy7:DSPE-PEG(2000)-CREKAandDSPE-
PEG(2000)-Cy7:DSPE-PEG(2000)-maleimide (10:90 molar ratio) dissolved in water
weremeasured (Zetasizer Nano ZS,Malvern,Worcestershire, United Kingdom,N 3).
2.3. Animal experiments
To assess the targeting abilities of Cy7- and Cy7-CREKA-micelle nanoparticles,
8e10 weeks old male C57BL/6 mice (Cat# 000664; Jackson Laboratories, Bar Harbor,
ME, USA) were intracranially injected with 4  105 GL261 murine glioma cells
suspended in 5 ml PBS into the right hemisphere of the brain. Tumors were allowed
to grow for 1 week before administration of 100 ml of 1 mM Cy7-CREKA-micelles,
Cy7-micelles, or PBS via tail vein injection. The fur was naired and removed, before
obtaining in vivo images at 1, 2, and 3 h post-injection using a Xenogen IVIS 200
imaging system (Caliper Life Sciences, Hopkinton, MA). Mice were then euthanized
via CO2 overdose and organs (e.g. brain, heart, lungs, liver, kidneys, spleen, large
intestines, and bladder) were excised at 3 h, 24 h, and 7 days post-injection and
imaged. Quantiﬁcation and comparisons of the ﬂuorescence signal were achieved
via Living Image software (PerkinElmer, Downers Grove, IL, USA, N  3). In order to
conﬁrm that the micelles could target brain tumors and that the act of injecting did
not allow for accumulation of micelles at the injury site, mice were intracranially
injected with 5 ml PBS to establish the brain injury model, and Cy7- and Cy7-CREKA-
micelles were administered and imaged after 24 h post-injection. All animal pro-
cedures followed NIH guidelines for the care and use of laboratory animals and were
approved by the University of Chicago’s Institutional Animal Care and Use Com-
mittee (Chicago, IL, USA).
2.4. Immunohistochemistry and histology
Following optical imaging, the brain, liver, and kidney were immediately frozen
and embedded in O.C.T. Tissue Tek (Tissue Tek, Sakura Finetek, Torrance, CA, USA)
before 10 mm samples were sectioned (Microm HM 525, Fisher Scientiﬁc, Pittsburg,
PA, USA). Tissue sections were stained with Hematoxylin & Eosin (H & E), scanned
(CRi Panoramic, PerkinElmer, Downers Grove, IL, USA), and analyzed with Pan-
noramic Viewer 1.14.53.0 software (3DHISTECH, Budapest, Hungary). For immuno-
histochemistry, tissue sections were ﬁxed with 4% paraformaldehyde, followed by
incubation with Image-iT FX signal enhancer (Invitrogen, Carlsbad, CA, USA) for
30 min at RT. Sections were washed with PBS and incubated overnight at 4 C with
an antibody against ﬁbrinogen (Santa Cruz Biotech, Santa Cruz, CA, USA, 1:100). The
next day, sections were incubated for 1 h at RT using goat, anti-rabbit IgG-FITC
(Santa Cruz Biotech, Santa Cruz, CA, USA, 1:100), and mounted using Molecular
Probes ProLong Gold anti-fade reagent with DAPI (Invitrogen, Carlsbad, CA, USA).
2.5. Statistical analysis
A Student’s t-test was used to compare means of pairs. Analysis of variance
(ANOVA)with NewmaneKeuls multiple comparison test post-hoc analysis was usedFig. 2. Characterization of CREKA-micelles. A) The CMC is approximately 1to determine signiﬁcant differences among three or more means. A p-value of 0.05
or less was considered to be signiﬁcant.
3. Results
3.1. Characterizations of micelles
The ﬁbrin-binding pentapeptide, CREKA, was conjugated to
DSPE-PEG(2000)-maleimide via a thioether linkage to cysteine, and
the CMC of resulting PAs was determined to be 9.3  107 mM
(Fig. 2A). Fluorescently-labeled non-targeting (Cy7-micelle) and
CREKA micelles (Cy7-CREKA-micelle) were constructed by mixing
DSPE-PEG(2000)-Cy7 with either DSPE-PEG(2000)-CREKA or
DSPE-PEG(2000)-maleimide in a 10:90 molar ratio, and the pres-
ence of spherical micelles with an average diameter of 7.6 1.2 and
8.2  1.2 nm was conﬁrmed via TEM and DLS (Fig. 2B and Table 1).
Zeta potentials of Cy7- and Cy7-CREKA-micelles were determined
to be 27.4  4.5 and 12.6  1.6 mV, respectively (Table 1).
3.2. Micelle targeting to gliomas
In order to assess passive targeting of Cy7-micelles via the EPR
effect and enhanced accumulation of Cy7-CREKA-micelles, micelles
were intravenously administered in an intracranial GL261 glioma
mouse model and assessed via optical imaging (Fig. 3). After 1 h in
blood circulation, the localization of Cy7-CREKA-micelles at the
tumor site was visible via in vivo imaging and the accumulation
increased with time (Fig. 4). When brains were excised and imaged,
both Cy7-micelles and Cy7-CREKA-micelles were localized at the
tumor site within 3 h post-injection and cleared by 7 days (Fig. 5A).
In contrast, no ﬂuorescence signal was found when micelles were
administered in a brain injury model (Fig. 5A). Both Cy7- and Cy7-
CREKA-micelles demonstrated increased accumulation from the
3 he24 h time points, but Cy7-CREKA-micelles accumulated to a
signiﬁcantly greater extent than their non-targeting counterparts
at each time point (3 h: 8.7  108 vs. 2.3  108 p/s/cm2/sr; 24 h:
1.6  109 vs. 1.7  108 p/s/cm2/sr; Fig. 5B). When samples were
sectioned and evaluated histologically, both Cy7- and Cy7-CREKA-
micelles showed bright, individual, punctate patterns of Cy7 ﬂuo-
rescence within the tumor region of the brain, and no Cy7 signal
was found in the non-tumor tissue (Fig. 6A). Notably, Cy7-CREKA
samples also showed a dimmer ﬂuorescence signal present
throughout the sample. Immunohistochemistry also conﬁrmed amM and B) TEM images conﬁrm the spherical shape of CREKA-micelles.
Fig. 3. Design of animal studies.
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(Fig. 6B).
3.3. Biodistribution of micelles
Fig. 7 shows the biodistribution of micelles throughout the liver,
spleen, kidneys, bladder, large intestines, heart, and lung at 3 h,
24 h, and 7 days after injection using optical imaging (Fig. 7). At all
time points, both Cy7- and Cy7-CREKA-micelles were found to beFig. 4. In vivo imaging of Cy7-CREKA-micelles. A) In vivo images show accumulation of Cy7
accumulation increases for up to 3 h.primarily localized in the liver. Micelles also showed greater
accumulation in the kidney and bladder when compared to the rest
of the organs. By 7 days, both types of micelles were mostly cleared
from circulation and were found to reside only within the liver.
3.4. Liver and kidney assessment
As the liver and kidney are vital organs for metabolism and
excretion, tissues were stained with H & E, examined using light-CREKA-micelles in the brain and B) quantiﬁcation of the ﬂuorescence signal conﬁrms
Fig. 5. Ex vivo imaging of the brain. A) Cy7-micelles and Cy7-CREKA-micelles localize to brain tumor tissue and are cleared by 7 days. No accumulation is seen in the injury model
after 24 h. B) Cy7-CREKA-micelles accumulate within tumor tissue to a greater extent than Cy7-micelles at 3 and 24 h post-injection. Asterisks denote statistical signiﬁcance
(p  0.05).
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Cy7-micelles, or Cy7-CREKA-micelle at all time points are pre-
sented. As seen in Fig. 8, no apparent tissue or cellular damage was
observed in mice injected with either micelles and were compa-
rable to images obtained from mice injected with PBS, and no
pathological changes were observed.
4. Discussion
The treatment of glioblastoma is limited due to the aggressive
natureof the tumorand the inability for complete surgical excision. AsFig. 6. Histological assessment of micelle and ﬁbrin distribution. A) Fluorescence images an
both Cy7-micelle and Cy7-CREKA-micelle treated mice. Additionally, dimmer areas of Cy7 w
tissues. B) Fibrin was present throughout the tumor region.a result, GBM prognosis remains poor, with a 14.6 month median
survival time despite interventions [1]. Chemotherapy against glio-
blastomahas not translated intomeaningful improvements inpatient
outcomedue to lowpermeabilityandpoorpenetrationacross theBBB
[23,24]. Furthermore, systemically delivered chemotherapy poses
challenges including high toxicity and numerous side effects [24]. In
contrast, the rational design of targeted delivery vehicles has the po-
tential to efﬁciently unload drugs to the tumor site, while sparing the
surrounding healthy tissue and the function of vital organs.
In this study, ﬂuorescently-labeled micelle nanoparticles func-
tionalized with the pentapeptide, CREKA, were intravenouslyd H & E staining exhibit punctate patterns of the Cy7 signal within the tumor tissue in
ere present in mice injected with Cy7-CREKA-micelles. No Cy7 was found in non-tumor
Fig. 7. Biodistribution of micelles. Fluorescence was measured at 3 h, 24 h, and 7 day time points in (1) liver, (2) spleen, (3) kidneys, (4) bladder, (5) large intestines, (6) heart, and (7)
lungs. Micelles localized primarily to the liver, kidneys, and bladder.
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to target other types of tumors in vivo by binding to ﬁbrin intra-
vascularly and ﬁbrin deposition is also present in primary and
metastatic brain tumors, CREKA-micelles were applied as targeting
agents for gliomas [18e20]. The CMC of micelles was close to 1 mM,
which is comparable to micelle systems composed of DSPE-
PEG(2000) and 100 ml of 1 mM micelle solution was chosen to be
administered in mice because the concentration remains above the
CMC even upon injecting into approximately 2 mL of circulating
blood volume (Fig. 1A) [21,25]. The conjugation of CREKA to DSPE-
PEG(2000)-maleimide slightly increased the micelle size from
7.6  1.2 to 8.2  1.2 nm (Table 1, Fig. 1B). As particles from 5 to
250 nm are reported to exhibit higher transport efﬁciency to tu-
mors, the nanoparticles obtained here are within the range of this
requirement [8,26e28]. The addition of the peptide also changed
the zeta potential of micelles from 27.4  4.5 to 12.6  1.6 mV.
The surface charge of Cy7-micelles can be attributed to the phos-
phate group of the DSPE tail, PEG molecules, and the maleimide,Fig. 8. Representative H and E staining of the liver and kidney upon micelle administratio
kidneys treated with micelles in comparison to the PBS-treated controls.which is increased by the addition of the arginine and lysine-
containing peptide.
Cy7 was chosen as the ﬂuorophore to be incorporated into mi-
celles because its excitation and emission wavelength in the near
infrared range is optimal to achieve both deep tissue penetration
and low auto-ﬂuorescence for in vivo imaging [29]. Fig. 4 conﬁrmed
Cy7-CREKA-micelles accumulate in the brain by 1 h and that the
amount of accumulation can be monitored and quantiﬁed through
in vivo imaging, supporting the possibility for quantitative di-
agnostics using this system. When brains were excised after 3 h,
24 h, and 7 days post-injection, ﬂuorescence was detectable in
tumors for both Cy7-micelles and Cy7-CREKA-micelles, conﬁrming
that the micelles passively target gliomas by the EPR effect and that
the CREKA-modiﬁed micelles can further increase retention by
active targeting (Fig. 5). Accumulation for both Cy7-micelles and
Cy7-CREKA-micelles between 3 h and 24 h post-injection was not
statistically signiﬁcant although slightly higher at the latter time
point, suggesting that our micelle delivery system has the potentialn. No morphological changes or tissue damage was demonstrated in A) livers and B)
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administration and is maintained for at least 24 h. Moreover, it is
possible that all of the ﬁbrin-binding sites of the tumor are occu-
pied by 3 h; since micelles were constructed with a molar ratio of
10:90 for Cy7- and CREKA-containing amphiphiles, future drug
delivery studies will alter the peptide amphiphile ratio to exploit
micelle binding and offer the most efﬁcient and highest amount of
therapy to the tumor site.
After 7 days, micelles were cleared from the brain. Notably, no
ﬂuorescence signal was found when either Cy7-micelles or Cy7-
CREKA-micelles were administered in a brain injury model. This
conﬁrms that the intracranial injection technique did not
contribute to micelle accumulation to the brain, but instead, mi-
celles target speciﬁcally to tumors via penetration of the compro-
mised BBB. Upon histological examination, the ﬂuorescence signal
followed the optical imaging trends in which Cy7-CREKA-micelles
accumulate in the tumor to a greater extent than Cy7-micelles
(Fig. 6). Concentrated, ﬂuorescent dots may represent micelles
entrapped within the tumor blood vessels or thrombi, whereas
dimmer regions of ﬂuorescence may represent extravascular
diffusion across the blood-tumor-barrier (BTB) of Cy7-CREKA-mi-
celles into the glioma tissue due to increased accumulation (Fig. 1)
[27]. In order to verify whether Cy7-CREKA-micelles bind to
intravascular ﬁbrin within gliomas, the presence of ﬁbrin was
determined via immunohistochemistry. However, upon processing
tissue sections for ﬁbrin detection, the Cy7 signal was quenched.
In addition to the inﬂuence of material properties of nano-
particles on the penetration and accumulation in tumor tissues,
previous studies have reported particle size to affect the clearance
mechanisms of nanoparticles [26,30e33]. Since both Cy7- and Cy7-
CREKA-micelles are approximately 8 nm in diameter, they fall in
the range of particles that are capable of both renal clearance via
the kidneys and bladder and elimination by macrophages in the
spleen and liver through the reticuloendothelial system (RES),
which is consistent with the biodistribution data found in Fig. 7
[34,35]. By 7 days, the majority of the micelles were cleared and
only remained within the liver conﬁrming RES to play a larger role
in clearance. H & E images conﬁrmed that the liver and kidney, key
organs involved in renal clearance and RES, showed no signs of
tissue damage and had morphologies that were similar to that of
PBS-treated controls, establishing the biocompatibility and safety
of these micelles as a targeted drug delivery system for the treat-
ment of glioblastoma.
5. Conclusions
Cy7-labeled micelles were modiﬁed with the ﬁbrin-binding
peptide, CREKA, to enhance the targeting of micelles to glioblas-
toma. Cy7-micelles and Cy7-CREKA-micelles were spherical in
shape and the addition of the pentapeptide increased the average
particle size and zeta potential from 7.6 to 8.2 nm, and 27.4
to12.6 mV, respectively. Upon intravenous injection into a mouse
model of intracranial glioma, Cy7-micelles passively accumulated
at the tumor site via the EPR effect, whereas Cy7-CREKA-micelles
displayed enhanced tumor homing via active targeting, conﬁrmed
by in vivo and ex vivo imaging and immunohistochemistry.
Importantly, neither Cy7-micelles nor Cy7-CREKA-micelles local-
ized to the brain in an injurymodel, conferringmicelle speciﬁcity to
brain tumors via penetration across the compromised BBB. Bio-
distribution of micelles showed high accumulation in the liver and
kidneys, which suggests both renal clearance and RES plays a role in
micelle elimination and organs showed no signs of cytotoxicity or
tissue damage determined via histological evaluation. Our study
demonstrates a new avenue for targeting glioblastoma, and future
studies will harness these capabilities to achieve highly efﬁcient,chemotherapeutic drug delivery for the treatment of malignant
gliomas.
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